Results 101 to 110 of about 29,210 (297)

Optimizing Ibrutinib Posology in Chronic Lymphocytic Leukemia Using a Semi‐Mechanistic Pharmacometric Framework

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Ibrutinib, a Bruton's tyrosine kinase (Btk) inhibitor, is a key therapy for chronic lymphocytic leukemia (CLL). In clinical practice, adverse events, such as hypertension, frequently necessitate dose reductions or treatment discontinuation. Emerging evidence suggests that reduced doses may retain clinical efficacy while mitigating toxicity ...
Eman I. K. Ibrahim, Lena E. Friberg
wiley   +1 more source

Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse

Biomarker Research, 2020
Background Ibrutinib, an irreversible Bruton Tyrosine Kinase (BTK) inhibitor, has revolutionized Chronic Lymphocytic Leukemia (CLL) treatment, but resistances to ibrutinib have emerged, whether related or not to BTK mutations.
Sarah Cadot, Carine Valle, Marie Tosolini, Frederic Pont, Laetitia Largeaud, Camille Laurent, Jean Jacques Fournie, Loic Ysebaert, Anne Quillet-Mary   +8 more
doaj   +1 more source

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

Blood, 2020
Treon et al provide early clinical data supporting a theoretical rationale for continuing ibrutinib in patients receiving the drug during COVID-19 illness.
S. Treon, J. Castillo, A. Skarbnik, J. Soumerai, I. Ghobrial, M. L. Guerrera, K. Meid, Guang Yang   +7 more
semanticscholar   +1 more source

Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group's large B‐cell lymphoma cohort

British Journal of Haematology, EarlyView.
The international prognostic index (IPI)‐driven trial inclusion criteria may have contributed to the failure of some of the first‐line trials in large B‐cell lymphoma (LBCL). GLA and LYSA collaborated to improve prognostic stratification in LBCL by analyzing data from trial cohorts and proposed the smIPI.
Umut Yılmaz, Esra Terzi Demirsoy, Fatma Keklik Karadağ, Uğur Hatipoğlu, Meral Uluköylü Mengüç, Ebru Pekgüç, Taner Tan, Eda Nuhoğlu Kantarcı, Metban Mastanzade, Ali Durdu, Merve Apaydın Kayer, Murat Özbalak, Tuğrul Elverdi, Asu Fergün Yılmaz, Deniz Gören, Tayfur Toptaş, Turgay Ulaş, Özgür Mehtap, Mehmet Sinan Dal, Olga Meltem Akay, Muhlis Cem Ar, Güray Saydam, Fevzi Altuntaş, Elif Birtaş Ateşoğlu, Burhan Ferhanoğlu   +24 more
wiley   +1 more source

Towards a chemo‐free approach for follicular lymphoma

British Journal of Haematology, EarlyView.
Summary The therapeutic landscape of follicular lymphoma (FL) is undergoing a transformative shift driven by the advent of novel chemo‐free strategies that challenge the traditional chemo‐oriented paradigms; this shift offers promising alternatives for both newly diagnosed and relapsed or refractory (RR) patients.
Stefano Luminari, Emiliano Barbieri, Maria Elena Nizzoli   +2 more
wiley   +1 more source

Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia

British Journal of Haematology, EarlyView.
Summary Ibrutinib is metabolized by cytochrome P450 3A (CYP3A) and poses challenges with drug interactions. We conducted a population‐based cohort study of Ontario residents aged ≥66 years who initiated ibrutinib for chronic lymphocytic leukaemia (CLL) to evaluate the frequency of potential drug interactions involving moderate/strong CYP3A inhibitors ...
Tuan Hoang, Matthew C. Cheung, David N. Juurlink, Kelvin K. W. Chan, Cindy Lau, Ning Liu, Husam Abdel‐Qadir, Anca Prica, Annette E. Hay, Abi Vijenthira, Lee Mozessohn   +10 more
wiley   +1 more source

Epidemiology, clinical characteristics and potential mechanism of ibrutinib-induced ventricular arrhythmias

Frontiers in Pharmacology
The Bruton’s Tyrosine Kinase Inhibitor, ibrutinib, has been widely employed due to its significant efficacy in B-cell lymphoma. However, the subsequent cardiac complications, notably atrial fibrillation (AF) and ventricular arrhythmias (VAs),associated ...
Yilin Pan, Yilin Pan, Yanan Zhao, Hangyu Ren, Hangyu Ren, Xintong Wang, Caixia Liu, Beibei Du, Kumaraswamy Nanthakumar, Ping Yang   +9 more
doaj   +1 more source

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study

Journal of Hematology & Oncology, 2021
Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL).
Michael Wang, Radhakrishnan Ramchandren, Robert Chen, Lionel Karlin, Geoffrey Chong, Wojciech Jurczak, Ka Lung Wu, Mark Bishton, Graham P. Collins, Paul Eliadis, Frédéric Peyrade, Yihua Lee, Karl Eckert, Jutta K. Neuenburg, Constantine S. Tam   +14 more
doaj   +1 more source

Ibrutinib-Associated Atrial Fibrillation

JACC: Clinical Electrophysiology, 2018
Ibrutinib, a novel and potent Bruton tyrosine kinase inhibitor, is an effective and well-tolerated treatment for a variety of B-cell lymphomas. However, its use is associated with an increased incidence of atrial fibrillation (AF), ranging from 4% to 16%. We reviewed the original clinical trials that led to the approval of ibrutinib, as well as several
David M. Venesy, Ana Barac, Tomas G. Neilan, Ghulam M. Chaudhry, Ajay K. Sharma, Sachin P. Shah, Salim S. Hayek, Sarju Ganatra, Syed S. Mahmood, Saurbha Dani, Anju Nohria, Richard D. Patten, John D. Groarke, David Martin   +13 more
openaire   +3 more sources

Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options?

European Journal of Haematology, EarlyView.
ABSTRACT Mantle Cell Lymphoma (MCL) is an aggressive B‐cell non‐Hodgkin lymphoma characterized by the hallmark t(11;14)(q13;q32) translocation, resulting in cyclin D1 overexpression. Predominantly affecting elderly males, MCL exhibits marked clinical and biological heterogeneity, ranging from indolent SOX11‐negative variants to highly proliferative ...
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source